兰德-Assessing-the-Preparedness-of-the-Health-Care-System-Infrastructure-in-Six-European-Countries-for-an-Alzheimers-Treatment_24页_352kb

Summary of "Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment"

Core Content

This study evaluates the readiness of six European countries—France, Germany, Italy, Spain, Sweden, and the United Kingdom—to diagnose and treat Alzheimer's disease if a disease-modifying therapy becomes available. The focus is on the potential mismatch between the expected number of patients and the available health care infrastructure, particularly in the context of early-stage Alzheimer's disease and mild cognitive impairment (MCI).

Main Findings

• Projected Peak Wait Times:
  Wait times for Alzheimer's treatment vary significantly across the six countries.

  • Germany: 5 months (first year without wait times: 2030)
  • France: 19 months (first year without wait times: 2033)
  • United Kingdom: 18 months (first year without wait times: 2042)
  • Spain: 16 months (first year without wait times: 2044)
  • Sweden and Italy: Wait times are constrained primarily by infusion delivery capacity, with clearing as early as 2030 in Germany and as late as 2044 in Spain.

• Capacity Constraints:
  Specialist capacity is the main limiting factor in France, the United Kingdom, and Spain.
  Treatment delivery capacity is a constraint in most countries, while biomarker testing is not a significant bottleneck in any of the countries studied.

• Impact of Therapy Availability (2020):
  If a disease-modifying therapy becomes available in 2020, it is estimated that over 1 million patients with MCI could progress to Alzheimer's dementia while on waiting lists between 2020 and 2044.

• Patient Journey Framework:
  The study uses a simulation model based on a Markov process to track transitions between disease states and a systems dynamics model to simulate health care capacity constraints. The model considers the following phases:

  1. Screening: Cognitive screening in primary care settings.
  2. Diagnosis: Evaluation by a dementia specialist and biomarker testing (CSF or PET).
  3. Treatment: Infusion delivery of the therapy.
  4. Outcomes: Reduction in progression from MCI to Alzheimer's dementia.

• Key Assumptions:

  • A disease-modifying therapy (targeting beta-amyloid) becomes available in 2020.
  • 80% of eligible individuals (age 55+) will be screened annually.
  • 50% of those screening positive for MCI will proceed to further evaluation.
  • 90% of confirmed MCI cases will undergo biomarker testing.
  • 45% of MCI patients are expected to have clinically relevant biomarker levels.
  • 80% of those testing positive for biomarkers will have no contraindications to treatment.
  • Treatment involves 14 intravenous infusions over one year, reducing the relative risk of progression by 50%.

Country-Specific Capacity Estimates

Key Recommendations

• A combination of reimbursement policies, regulatory frameworks, and workforce planning is necessary to address the capacity constraints.
• Innovation in diagnosis and treatment delivery is critical to improving access and reducing wait times.
• Optimizing specialist workforce and expanding infusion delivery capacity are essential for ensuring timely care.
• Public health planning must consider the long-term implications of an aging population and the potential surge in demand for early diagnosis and treatment of Alzheimer's disease.

Conclusion

The study highlights the urgent need for health care systems in these six European countries to prepare for the potential surge in demand for Alzheimer's disease diagnosis and treatment. Without adequate capacity expansion, millions of patients may be unable to access early-stage therapies, leading to preventable progression to Alzheimer's dementia. The findings emphasize the importance of proactive policy development and infrastructure investment to ensure equitable and timely access to care.